Gilead Sciences - AI Stock Analysis

Analysis generated October 11, 2025

Gilead Sciences is a biopharmaceutical company primarily focused on antiviral drugs used in the treatment of HIV, Hepatitis B, and Influenza, among other diseases. With a history of strong drug portfolio performance, the company commands significant market share in the antiviral segment. Known for its innovation and robust R&D pipeline, Gilead continues to seek breakthroughs in new therapeutic areas.

Fundamental Analysis

The revenue for the last quarter was $7.08B, marking a 6.21% increase compared to the previous quarter. Compared to the same quarter last year, revenue increased by 1.84%. This suggests a consistent upward trajectory in sales and a positive year-over-year growth.

Net income for the last quarter stood at $1.96B, reflecting a significant 49.05% increase compared to the prior quarter and a 21.44% increase year-over-year. This indicates efficient cost management and enhanced profitability.

The earnings before interest, taxes, depreciation, and amortization (EBITDA) for the last quarter was $3.37B, up by 29.52% quarter-over-quarter and 13.07% year-over-year. These sharp increases in EBITDA signify strong operational performance with effective revenue and cost controls.

The current price-to-earnings (P/E) ratio is 23.16, sitting within a standard range. This implies the stock is reasonably valued relative to its earnings. Company insiders have been selling their stock recently, which normally would be considered a bearish signal warranting further scrutiny.

Technical Analysis

Today’s stock price of $117.18 represents a 0.12% increase from a month ago, indicating a short-term positive trend. Additionally, there is a substantial 42.07% rise when compared to the same time last year, showcasing a robust long-term upward trend.

The current SMA10 (Simple Moving Average over 10 days) is $114.83, higher than the previous SMA10 of $114.23, suggesting a continuing upward trend in price movement.

The Relative Strength Index (RSI) is 75.2, indicating that the stock might be overbought and could be due for a price correction. Overbought conditions can often precede a bearish phase.

Alternative Data Analysis

Job postings at Gilead Sciences number 291 and have remained stable, reflecting steady hiring activity and a stable business environment. Employee sentiment is neutral, neither strongly positive nor negative, indicating a balanced internal outlook.

Customer acquisition metrics show an estimated 550,000 visitors to Gilead’s webpage, a 7% increase over the past couple of months. This uptick is a bullish trend, suggesting potential growth in customer interest and acquisition.

Gilead Sciences maintains around 73,000 followers on Twitter, with no significant fluctuations recently. This relatively stable social media engagement suggests consistent interest and brand presence.

AltIndex's AI score for Gilead Sciences stands at 59, indicating a 'hold' signal based on the blend of fundamental, technical, and alternative data metrics.

Conclusion and Recommendation

Gilead Sciences demonstrates stable growth with continued revenue and net income increases. Positive EBITDA and a reasonably priced P/E ratio coupled with a bullish trend in stock price reinforce its strong market positioning. However, the recent insider selling and high RSI may indicate potential near-term volatility. Alternative data supports a stable to mildly positive outlook on customer and employee fronts. Altogether, Gilead Sciences presents as a 'hold' with room for re-evaluation upon any notable changes in financial metrics or market conditions.

Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.